Retreatment of patients with chronic hepatitis C

Hepatology

Volumn 36, Issue 5 I, 2002, Pages

  Shiffman, Mitchell L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

BLOOD LEVEL; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDUCED DISEASE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; RETREATMENT; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; RECURRENCE; RETREATMENT;

EID: 0036830199     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.36816     Document Type: Conference Paper

References (23)

1. National Institutes of Health Consensus Development Conference Panel Statement: Management of hepatitis C. Hepatology 1997;26(suppl 1):2S-10S.
2. McHutchinson JG, Gordon S, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman Z, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: N Engl J Med 1998;339:1485-1492.
3. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomized trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432.
4. Reichard O, Schvarcz R, Weiland O. Therapy of hepatitis C: alpha interferon and ribavirin. Hepatology 1997;27(Suppl 1);108S-111S.
5. Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman ML, Reindollar R, Goodman ZD, et al. Peginterferon-alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001;358:958-965.
6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
7. Lindsay KL. Therapy of hepatitis C: Overview. Hepatology 1997;27(Suppl 1):71S-77S.
8. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology 2002;36(suppl 1):S114-S120.
9. Shiffman ML, Hofmann CM, Thompson EB, Ferreira-Gonzalez A, Contos MJ, Koshy A, Luketic VA, et al. Relationship between biochemical, virologic and histologic response during interferon treatment of chronic hepatitis C. Hepatology 1997;26:780-785.
10. Shiffman ML. Histologic improvement in response to interferon therapy in chronic hepatitis C. Viral Hepat Rev 1999;5:27-43.
11. Shiffman ML, Hofmann CM, Gabbay J, Luketic VA, Sterling RK, Sanyal AJ, Contos MJ, et al. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: Effects of higher doses of interferon and ribavirin combination therapy. Am J Gastroenterol 2000;95:2928-2935.
12. Cheng SJ, Bonis PAL, Lau J, Pham NQ, Wong JB. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: A meta-analysis of controlled and uncontrolled trials. Hepatology 2001;33:231-240.
13. Cummings KJ, Lee SM, West ES, Cid-Ruzafa J, Fein SG, Aoki Y, Sulkowski MS, et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon. JAMA 2001;285:193-199.
14. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon S, Trepo C, Shiffman ML, et al. Recombinant interferon alfa-2b alone or in combination with ribavirin for retreatment of interferon relapse in chronic hepatitis C. N Engl J Med 1998;339:1493-1499.
15. Fried MW. Side effects of therapy and their management. Hepatology 2002;36(suppl 1):S237-S244.
16. Ohnishi K, Matsuo S, Matsutani K, Itahashi M, Kakihara K, Suzuki K, Ito S, et al. Interferon therapy for chronic hepatitis C in habitual drinkers: Comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996;91:1374-1379.
17. Peters M, Terrault N. Alcohol use and hepatitis C. Hepatology 2002;36(suppl 1):S220-S225.
18. Shiffman ML. Management of interferon therapy non-responders. Clin Liver Dis 2001;5:1025-1043.
19. Jacobsen I. Pegylated interferon alfa-2b plus ribavirin in patients with chronic C: Atrial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy nonresponders. Gastroenterology 2002;122:A626.
20. Shiffman ML. Retreatment of HCV non-responders with peginterferon and ribavirin: Results from the lead-in phase of the hepatitis C antiviral long term treatment against cirrhosis (HALT-C) trial [Abstract]. Hepatology 2002;36:295A.
21. Shiffman ML, Hofmann CM, Sterling RK, Luketic VA, Contos MJ, Sanyal AJ. A randomized, controlled trial to determine if continuing ribavirin as monotherapy in patients who responded to interferon/ribavirin combination therapy will enhance sustained virologic response. J Infect Dis 2001;184:405-409.
22. Shiffman ML. Histologic improvement in response to interferon therapy in chronic hepatitis C. Viral Hepat Rev 1999;5:27-43.
23. Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, Ferreira-Gonzalez A, et al. A randomized, controlled trial of maintenance interferon for treatment of chronic hepatitis C non-responders. Gastroenterology 1999;117:1164-1172.